World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board
09 févr. 2017 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications...
PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
10 janv. 2017 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Jan. 10, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
07 déc. 2016 08h50 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
15 nov. 2016 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Nov. 15, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
24 oct. 2016 12h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 24, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
19 oct. 2016 15h15 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website
17 oct. 2016 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 17, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission
13 oct. 2016 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 13, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update
10 oct. 2016 08h00 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 10, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Explores Product Expansion with Strategic Partner(s); Successfully Presents at Two Financial Conferences in September
28 sept. 2016 10h30 HE
|
PetLife Pharmaceuticals, Inc.
Hancock, MD , Sept. 28, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"), the developer of Vitalzul™, a new generation of high potency veterinary cancer...